The expression of multidrug resistance (MDR) molecule in acute leukemia and lymphoma.
Multidrug resistance (MDR) is associated with expression of P-glycoprotein in the malignant cells as the one of known mechanisms for this phenomenon. The isolated blast cells of 60 patients with acute leukemia and non-Hodgkin's lymphoma (NHL) were assayed for the expression of P-glycoprotein (P-170) with MRK16 antibody. The frequency of P-170 expression was studied in the different subtypes of leukemia and NHL based on blasts phenotype. In acute leukemia and lymphoma with B cell lineage of blast cells the percentage of P-170 positive samples was 41.3%, in the non-lymphoblastic leukemia--35.3% and the T cell lineage--75% of P-170 positive samples. The expression of P-170 molecule was associated with: 1. T cell origin of blasts, 2. lymphoma form of proliferation. The P-170 assay selects the group of patients with higher risk of drug resistance for modified therapy.
Pituch-Noworolska
A
A
Department of Clinical Immunology and Microbiology, Polish-American Childrens Hospital, Kraków.
Gawlicka
M
M
Balwierz
W
W
D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1 / Q000032:analysis*; D018432:Drug Resistance, Multiple / Q000502:physiology*; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy / Q000503:physiopathology*; D008213:Lymphocyte Activation / Q000502:physiology; D008228:Lymphoma, Non-Hodgkin / Q000737:chemistry* / Q000188:drug therapy; D010641:Phenotype; D012008:Recurrence
D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1